Supprelin® LA (histrelin acetate subcutaneous implant)

Supprelin LA is covered only for the FDA‑approved pediatric indication—treatment of children with central precocious puberty—and other indications or adult use are excluded. Coverage requires documentation of the diagnosis, is limited to a 12‑month approval, and follows the recommended 50 mg subcutaneous implant in the upper arm replaced every 12 months.

"Supprelin ® LA (histrelin acetate subcutaneous implant) is indicated for the treatment of children with central precocious puberty."

Sign up to see full coverage criteria, indications, and limitations.